lymphomas (Figure 1B
. A strict definition of non-nasal NK/T-cell lymphoma requires absence of nasal involvement, shown by random nasopharyngeal biopsies and PET/CT. 23 Such stringent definition was not utilized in previous series of "non-nasal" NK/T-cell lymphomas, 18 which probably described many cases of disseminated nasal lymphomas. With improved treatment strategies, primary sites of presentation are no longer an independent prognostic indicator. 24 Rarely, the lymphoma can present fulminantly with widespread systemic dissemination and involvement of the marrow and peripheral blood ( Figure   1C ). 11, 22, 25 These cases, referred to as disseminated NK-cell lymphoma/leukemia, or aggressive NK cell leukemia according to WHO classification, 9 are catastrophic with an extremely poor survival measured only in weeks.
Molecular pathogenesis
Early studies by our group showed specific karyotypic and genomic aberrations.
26-28
Based on the observations that 6q21 is frequently deleted, 26-29 genes residing in this region, including FOXO3, PRDM1 and HACE1, have been shown to be putative tumor suppressor genes. [30] [31] [32] The gene PRDM1 (alias BLIMP1) is particular interesting, because it regulates the maturation, homeostasis and proliferation of NK-cells. 33 Gene expression profiling (GEP) has shown patterns different from normal NK cells and other T-cell lymphomas. [34] [35] [36] Several oncogenic pathways are activated, including Notch-1, Wnt, JAK/STAT, AKT, and NFκB.
34-36

Diagnosis
Extensive necrosis often hampers histopathologic diagnosis, so surgeons should obtain biopsies as large as feasible. The specimen should be sent fresh for cryostat sectioning, to distinguish between surface-and cytoplasmic-CD3 expression and hence T-cell and NKcell lymphomas. If only paraffin material is available, the diagnosis can still be made, provided that CD56, EBER and cytotoxic molecules are positive. 8 In doubtful cases, TCR rearrangement studies should be performed. In metastatic sites, lymphoma cells may lose CD56, 39 so that EBER-ISH is more reliable for defining lymphoma infiltration. 40 EBV is a diagnostic requisite, and EBV-negative cases should be diagnosed as peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). 8 Cases that are EBV-positive but negative
for CD56 or cytotoxic molecules should also be classified as PTCL-NOS.
8
Diseases requiring differentiation from NK/T-cell lymphomas
Chronic active EBV infection is a rare disease observed in Asian populations, Mosquito-bite hypersensitivity is an interesting disorder observed in Asian and South American populations. 42 Patients report papulovesicular skin lesions attributed to bites from mosquito or other arthropods (whether they really are insect-bites have never been confirmed scientifically); which progress to ulceration and scarring. In serious cases, fever, lymphadenopathy and hepatosplenomegaly occur. Most prevalent in childhood, it overlaps Figure 2A ).
Lymphomatoid gastropathy 44 or NK-cell enteropathy 45 are benign conditions that may be mistaken as lymphomatous. They may be discovered incidentally during endoscopy as small (about 1 cm) edematous lesions with superficial ulcerations or hemorrhage, occuring most often in the stomach, followed by the duodenum, small and large bowel. Histologically, there is mucosal infiltration by atypical cells with an NK-cell phenotype (surface-CD3-, cytoplasmic-CD3ε+, CD56+, cytotoxic molecules+, TCR-). EBV is not present. The lesions self-regress, but may recur. It is a benign disease.
Initial evaluation and staging
A nasal panendoscopy is performed irrespective of the initial site(s) of presentation,
23
with suspicious lesions biopsied. In our center, random nasopharyngeal biopsies are performed even when no lesions are seen. As hepatitis B virus (HBV) carrier rates are high in populations at risk of NK/T-cell lymphoma, HBV testing should be routine; and anti-viral prophylaxis administered to carriers during chemotherapy. 46 In bilateral marrow trephine biopsies, EBER-ISH is a must for detecting occult involvement.
39,40
NK/T-cell lymphomas are 18-fluorodeoxyglucose-avid (Figure 2 B-E), 19, 20 and PET/CT is the recommended imaging modality. The standard uptake value maximum (SUVmax) is lower in NK/T-cell lymphoma than aggressive B-cell lymphomas. An SUVmax of > 10 should prompt examination for co-existing neoplastic or infective processes.
19,20
When PET/CT is unavailable, CT or magnetic resonance imaging (MRI) may be 
Quantification of circulating plasma EBV DNA
EBV infection is latent and not lytic in the lymphoma cells. During tumor cell apoptosis, EBV genomic fragments are released into the circulation, which can be quantified by polymerase chain reaction. As circulating lymphoma cells are not found, the appropriate material to be examined is plasma. Whole blood is not ideal, because it contains EBVinfected memory B-cells, which can introduce considerable and unpredictable errors. Early studies by us showed that plasma EBV DNA was correlated with tumor load, with high EBV DNA correlating negatively with survivals. 47 These observations have since been confirmed. 48 Serial EBV DNA monitoring is useful for assessing response and detecting recurrence.
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General principles of treatment
Current treatment strategies are adopted from retrospective analyses and phase II studies. For localized disease, radiotherapy together with chemotherapy is the standard approach. 11, 22, 23 Meticulous radiotherapy planning with MRI or PET/CT is necessary to cover all involved areas, and a dose not less than 50 Gy should be delivered. Lower doses results in high in-field failure rates. In disseminated NK/T-cell lymphomas, systemic chemotherapy remains the mainstay of treatment. The role of hematopoietic stem cell transplantation (HSCT)
has not been prospectively evaluated.
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Treatment of localized early-staged nasal lymphomas
Combined chemotherapy-radiotherapy is standard. NK/T-cell lymphoma is radiosensitive. In studies employing radiotherapy alone (typically around 50 Gy), overall response rates (ORR) had varied between 77-100%, with complete response (CR) rates ranging from 52-100%. The dose and the radiation field are important considerations. Radiation dose of ≥ 50 Gy gave better response rates. An extended field encompassing all macroscopic lesions, paranasal sinuses, palate, and nasopharynx also resulted in lower local failure rates, when radiotherapy was employed alone. 54 The toxicity of such an extended field might be alleviated by intensity-modulated radiotherapy, without affecting the treatment results.
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However, the systemic relapse rates were as high as 25-40%, 50 suggesting that dissemination might have happened in these apparently localized nasal NK/T-cell lymphomas. These observations were made before the advent of PET/CT. Whether patients with localized nasal lymphoma defined by PET/CT may fare better with radiotherapy alone is undefined. Given the current data, radiotherapy alone is inadequate and chemotherapy is needed to decrease systemic failure.
Chemo-radiotherapy with anthracycline-based chemotherapy
Anthracycline-based regimens followed by involved-field radiotherapy are unsatisfactory. In an earlier retrospective study using 4 cycles of CHOP (cyclophosphamide, doxorubicine, vincristine and prednisolone) followed by involved-field radiotherapy (45Gy)
for stage I/II nasal lymphoma, the CR rate was merely 58%, with a 3-year overall survival (OS) of 59%. 56 Another disappointing observation was that 65% of patients had disease progression during CHOP. 56 Further attempts to improve the efficacy of CHOP-based regimens by increasing cycle numbers and drug dosages, or adding more chemotherapeutic agents, had not been successful. 50 Hence, CHOP-based chemotherapy is not recommended for NK/T-cell lymphoma.
The poor response may be due to intrinsic properties of the lymphoma. NK-cells express very high P-glycoprotein concentrations. This property is retained in NK/T-cell lymphomas, resulting in a multidrug resistance (MDR) phenotype. 57 Therefore, non-MDR dependent drugs are now incorporated in protocols specifically designed for NK/-T cell lymphomas.
Concurrent chemo-radiotherapy
Two recent prospective trials studied chemotherapy given concurrently with radiotherapy, trying to exploit the additional benefits of radiosensitization. 58, 59 In 27 patients with stage I/II nasal lymphomas, concurrent radiotherapy (50 Gy) and 3 cycles of 2/3DeVIC
(dexamethasone, etoposide, ifosfamide and carboplatin) ( Table 1 ) gave an ORR of 81%, with CR achieved in 77%. 56 The 5-year OS 70%, and the 5-year progression-free survival (PFS) was 63%. 60 Main toxicities were myelosuppression (grade 3/4 neutropenia: 93%) and radiation-related mucositis (grade 3: 30%). In another study, 30 patients with localized disease were treated with concurrent radiotherapy (40 Gy) and cisplatin, followed by 3 cycles of VIPD (etoposide, ifosfamide, cisplatin and dexamethasone) ( Table 1) . 59 The ORR was 83%, with CR achieved in 80%. The 3-year OS and PFS were 86% and 85%. Local and systemic relapse was found at the same rate of 6.6%. Two patients died of infections.
L-asparaginase-based chemotherapy with sandwiched radiotherapy
L-asparaginase as a single agent was found to be effective for relapsed/refractory NK/T-cell lymphomas. 61 Based on these observations, L-asparaginase has been incorporated into several regimens. A recent phase II study examined 26 patients with stage I/II nasal lymphoma treated with the LVP regimen (L-asparaginase, vincristine, and prednisolone) (Table 1) for 6 courses, with sandwiched radiotherapy after two courses. 62 After 2 cycles, the ORR was 92%, with CR achieved in 42%. After completion of radiotherapy (56 Gy) and 2-4 cycles of LVP, the ORR was 89%, with CR achieved in 81%. Grade 3 leucopenia was observed in 2.7% of patients, and grade 3 radiation-related mucositis in 23.1%. With a median follow-up of 27 months, the 2-year OS and PFS were 88.5% and 80.6%.
A slightly more intense regimen GELOX (gemcitabine, L-asparaginase, and oxaloplatin) ( Table 1) had been evaluated in a prospective study. 63 In 27 stage I/II patients, 2 cycles of treatment resulted in an ORR of 93%, with CR achieved in 56%. After sandwiched radiotherapy (56 Gy) and 2-4 cycles of GELOX, the ORR was 96%, with CR achieved in 74%. With a median follow-up of 27 months, the 2-year OS and PFS were both 86%. The local and systemic relapse rates were 15% and 11%. Grade 3/4 leucopenia developed in 33.3% of patients, and grade 3 radiation-related mucositis in 15%.
The most intense protocol in early-staged nasal lymphomas is the regimen SMILE (dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide). In a prospective study of 29 patients with newly-diagnosed nasal lymphomas, 24 interim analysis after 2-3 courses showed an ORR of 86%, CR achieved in 69%. After sandwiched involved-field radiotherapy (50 Gy) and 3-4 cycles of SMILE, the ORR was increased to 89.7%, with CR rates unchanged. These results showed that response to SMILE was rapid and seen even after 2 cycles. Furthermore, remission was durable with 90% of patients remaining in CR during follow-up. Grade 3/4 neutropenia occurred in 61% of patients. There was a regimen-related mortality of 7%.
Allergic reactions to L-asparaginase and even anaphylactic shock may occur.
Therefore, a skin test is recommended before each infusion. 24 In patients developing allergic reactions, Erwinia asparaginase should be used. Other precautions of using L-asparaginase containing regimens have been presented elsewhere.
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Rational choice of therapy in localized early-staged nasal lymphomas
Current data indicate that regimens employing non-MDR dependent drugs together with radiotherapy give very good ORR, CR rates and survivals (Table 2 ). There is no clear evidence that concomitant radiotherapy/chemotherapy is necessary, as sequential chemotherapy/radiotherapy gives comparable results. Logistic difficulties of arranging timely radiotherapy make it unlikely that concurrent chemo-radiotherapy can be used routinely outside clinical trials. Furthermore, sequential chemotherapy/radiotherapy usually means that radiotherapy is given in CR or very good partial remission, so that radiotherapy is better
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From tolerated. Sequential chemotherapy/radiotherapy is therefore preferred. When used together with chemotherapy, the necessary dose of radiotherapy has not been critically examined.
Because long-term toxicity of radiotherapy is rarely reported, it seems reasonable to employ a conventional dose of at least 50 Gy in combination with chemotherapy. For patients intolerant of chemotherapy because of serious medical co-morbidities, radiotherapy alone may be acceptable, if PET/CT clearly shows localized nasal disease.
Treatment of localized disease outside the nasal region
Reports of localized NK/T-cell lymphoma outside the nasal areas are scanty. Studies examining "non-nasal" lymphomas were performed before PET/CT was available, so it was unclear if they were genuinely non-nasal without nasal primaries. However, taken at face value, non-nasal lymphomas had poor outcomes with CHOP, radiotherapy or their combination. 18 In a retrospective study of 13 patients with localized non-nasal NK/T-cell lymphoma (skin/soft tissue, n=10; gastrointestinal, n=3), CHOP-based chemotherapy with sandwiched radiotherapy or surgery resulted in an ORR of 69% and CR in 54%. 64 However, CR was brief and 57% of patients relapsed and died. The 3-year OS was only 50%. In another retrospective analysis of 20 patients with skin NK/T-cell lymphoma, radiotherapy (N=5) gave a higher CR rate than chemotherapy (N=15) (80% versus 40%). Radiotherapy with or without chemotherapy also resulted in better OS than chemotherapy. 65 In another retrospective study where PET/CT was used to exclude occult nasal primaries, 11 patients with non-nasal lymphomas treated with SMILE had an ORR of 72.7%, with CR achieved in 54.5%.
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Current data indicate that localized non-nasal lymphomas might not fare as well as nasal lymphomas. Non-nasal lymphomas of any stage therefore should be treated with systemic chemotherapy with involved-field radiotherapy if applicable.
Treatment of advanced-stage, and relapsed/refractory NK/T-cell lymphoma
Combination chemotherapy remains the mainstay of treatment. In a phase II study of
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From the SMILE regimen, 38 patients (newly-diagnosed stage-IV disease, n=14; first relapse, n=14; primary refractory disease, n=4) were treated. 66 The ORR for newly diagnosed stage-IV, relapsed, and primary refractory diseases after 2 cycles of SMILE were 80%, 93% and 25% respectively, the corresponding CR rates being 40%, 64% and 0%. With a median follow-up of 24 months, the 1-year OS and PFS were 55% and 53%. Patients with relapsed disease had the best outcome (OS: 79%; PFS: 71%), followed by newly-diagnosed stage-IV disease (OS: 45%; PFS: 45%), and primary refractory disease (OS: 25%; PFS: 25%). Grade 3/4 neutropenia occurred in all patients, with serious infections in 61% of them. There were two therapy-related mortalities.
In another prospective study that examined relapsed/refractory patients treated with SMILE outside a trial setting, the ORR was 77%, with CR achieved in 66%. 24 The estimated 5-year OS was 52.3%; the 4-year disease-free-survival (DFS) was 68.2%. Interestingly, these survivals were comparable to those of newly-diagnosed patients. However, 72.7% of patients developed grade 3/4 neutropenia, and treatment-related mortality was 7%.
A multi-centered phase II study examined another L-asparaginase-based regimen in relapsed/refractory NK/T-cell lymphoma. 16 Nineteen patients were treated with 3 cycles of AspaMetDex (L-asparaginase, methotrexate, and dexamethasone) ( Table 1 ). The ORR was 78%, with CR achieved in 61%. With a median follow up of 26 months, the estimated 2-year OS and PFS were both around 40%. Grade 3/4 neutropenia developed in 44.4% of patients.
Current data therefore indicate that advanced-staged and relapsed/refractory NK/Tcell lymphomas should be treated with L-asparaginase containing regimens that incorporate non-MDR dependent drugs.
Treatment of aggressive NK cell leukemia
Few data were available on the treatment of aggressive NK-cell leukemia. In a retrospective series of 22 patients, 13 patients were treated with anthracycline-containing 25 The median survival was merely 58 days. However, occasional survivals had been reported in patients treated with L-asparaginase containing regimens, followed by allogeneic hematopoietic stem cell transplantation (HSCT) in patients who showed a response.
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Follow-up of NK/T-cell lymphoma patients in remission
Because of chronic infection due to tumor obstruction, or radiotherapy-induced mucosal damage, linings of the nasal cavity and paranasal sinuses are often thickened, making it difficult to monitor by CT or MRI for disease recurrence. PET/CT gives a functional and anatomical assessment of lymphoma status, and is the recommended followup investigation. 23 PET/CT-positive cases should be re-biopsied, as infection may also result in FDG-uptake. Plasma EBV DNA is a sensitive surrogate biomarker of lymphoma load.
23,47
Patients in apparent remission, but with EBV DNA either persistently detectable, or rising from a previous unquantifiable level, will invariably relapse; indicating that they will require additional therapy. 23 Serial plasma EBV DNA quantification is therefore important in the follow-up of NK/T-cell lymphoma patients in remission. It should be performed on a longterm basis, as the lymphoma is known to relapse after even decades of remission.
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Management of relapsed NK/T-cell lymphomas
For patients relapsing after radiotherapy or combined radiotherapy and anthracyclinecontaining chemotherapy, the use of an L-asparaginase containing regimen is highly efficacious. 16, 24, 66 The optimal salvage treatment of patients relapsing after receiving Lasparaginase containing regimens as primary treatment is undefined. Recent evidence suggests that gemcitabine-containing regimens may be effective in these patients, 69 which will require further validation. As with other aggressive lymphomas, relapsed patients achieving a remission again should be considered for high-dose chemotherapy with hematopoietic stem cell support. interim PET/CT findings should also be considered in the construction of future prognostic models.
Role of HSCT in the management of NK/T-cell lymphoma
The use of HSCT has been explored in NK/T-cell lymphomas. 49, 74 However, most studies contained small number of patients, with heterogeneous indications, inclusion criteria and HSCT protocols, so that results are difficult to interpret. Furthermore, the optimal timing, conditioning regimen, source of HSC, and whether a graft-versus-lymphoma effect is present in the allogeneic setting, are still undefined. 
Autologous HSCT
A retrospective analysis of 58 published cases of autologous HSCT had shown that patients transplanted in remission had significantly superior outcome compared with those in refractory disease or non-remission. 74 In another study, 47 patients undergoing autologous HSCT were examined. 75 With a median follow-up of 117 months, the estimated 5-year OS was 56%, which was not different from that of a historical matched control group (48%, p=0.13). The transplant-related-mortality (TRM) was 9%. Disease status pre-HSCT was also the most significant prognostic factor.
Although data of autologous HSCT are not plentiful, some deductions are possible.
Early-staged nasal lymphomas treated with combined chemotherapy and radiotherapy have results comparable with those of autologous HSCT. 74 Therefore, frontline HSCT is not warranted in these patients. Patients not achieving a remission fare poorly with HSCT, and novel treatment modalities are preferred. For patients with poor-risk or advance-staged lymphoma in remission, whether autologous HSCT improves outcome as compared with newer regimens such as SMILE remains unclear. Autologous HSCT is best tested in clinical trials.
Allogeneic HSCT
A retrospective study analyzed 28 patients with NK-cell malignancies receiving myeloablative (n=23) and reduced-intensity conditioning (RIC) (n=5) HSCT. 74 Bone marrow (n=8) and mobilized peripheral blood HSC (n=20) were obtained from 26 sibling-and 3 unrelated-donors. With a median follow up of 34 months, the 2-year OS and PFS were 40% and 34%. Grade 3/4 acute graft-versus-host disease (GVHD) developed in 14% of patients.
The overall TRMs for the myeloablative and RIC groups were 30% and 20% respectively. In another retrospective analysis, 12 patients with NK/T-cell lymphoma undergoing myeloablative (75%) or RIC allogeneic HSCT were studied. 76 The majority (67%) of patients had stage IV disease. HSC sources were cord blood (n=5), bone marrow from related-donors (n=2), and siblings (PBHSC, n=3; bone marrow, n=2). With a median follow up of 16 months, the 3-year OS and PFS were 55% and 53%. TRM was 8%.
With the limited data available, patients with advanced or relapsed lymphoma in remission can be offered allogeneic HSCT, preferably in a trial setting.
Future perspectives
In the last two decades, after NK/T-cell lymphomas have been recognized as distinct clinicopathologic entities, treatment outcome has improved considerably. Our current recommendations, incorporating our experience and that in the literature, are presented schematically in figure 3 . Continued efforts should be devoted to improving chemotherapeutic regimens, identifying better prognostic scores, and defining the role of HSCT ( Figure 3 ). Clinicians should be ready to translate findings from basic and genomic studies into targeted therapy, an approach that holds much promise in the treatment of other types of aggressive lymphomas.
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Legends Figure 1. Different clinical forms of NK/T-cell lymphomas.
A. Nasal lymphoma, showing an initial ulcer (left) that ultimately perforated into the oral cavity, creating a communication between the oral cavity and the nasal cavity. Such a lesion had been in the past referred to as "lethal midline granuloma"
B. Lymphoma initially localized to the calf, presenting as non-healing ulcers. Positron emission tomography computed tomography showed occult nasal involvement. This case could be erroneously classified as "non-nasal" lymphoma.
C. Aggressive NK-cell leukemia, showing neoplastic cells that were large granular lymphocyte in morphology in the peripheral blood, and in the bone marrow (arrow).
Figure 2. Clinical images of NK/T-cell lymphoma
A. A large ulcer that on biopsy showed NK/T-cell lymphoma. Scars (arrows) were attributed by the patient to be due to ulcers that healed from previous mosquito bite hypersensitivity, occurring over a period of decades. There was almost complete healing of the ulcer after two courses of SMILE (right side). 
